Chemistry:VK2809
From HandWiki
VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis[1][2] and is also being investigated for glycogen storage disease type Ia.[3]
In 2023, Viking Therapeutics filed a lawsuit against the developer of ASC41, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.[4][5]
References
- ↑ "VK2809". https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2809/.
- ↑ Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)" (in en). Expert Opinion on Investigational Drugs 29 (2): 99–101. doi:10.1080/13543784.2020.1708899. ISSN 1354-3784. PMID 31868036.
- ↑ Zhou, Jin; Waskowicz, Lauren R.; Lim, Andrea; Liao, Xiao-Hui; Lian, Brian; Masamune, Hiroko; Refetoff, Samuel; Tran, Brian et al. (1 August 2019). "A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia". Thyroid 29 (8): 1158–1167. doi:10.1089/thy.2019.0007. ISSN 1050-7256. PMID 31337282.
- ↑ "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. https://www.fiercebiotech.com/biotech/viking-accuses-chinese-biotech-ruse-raid-trade-secrets-and-make-nash-cache.
- ↑ "Viking Therapeutics accuses competitor of pilfering proprietary information". Chemical & Engineering News. January 9, 2023. https://cen.acs.org/pharmaceuticals/drug-development/Viking-Therapeutics-accuses-competitor-pilfering/101/web/2023/01. "Viking infers that ASC41 is Ascletis’s version of—if not the same compound as—VK2809"
 |  |
